Browse Newsroom

InsuLife Joins Legemiddelindustrien – the Association of the Pharmaceutical Industry in Norway

July 29, 2022

We are proud to announce that InsuLife has been accepted as a member of Legemiddelindustrien (LMI). The association aims to protect the professional interests of its members. LMI plays a key political role in setting policies regarding the industry in Norway and works to make the contributions from pharmaceutical industry visible within the community.

The trade organization has 65 members with close to 4000 employees in Norway and represent over 80% of pharmaceutical sales. LMI is an innovative trade organization that tries to influence commercial, nutritional and health policies and national visions on behalf of its member companies.

"We welcome InsuLife as a new member in LMI," says Karita Bekkemellem, Managing Director of LMI.
"InsuLife is developing an exciting technology which can simplify everyday life for people using insulin, increase quality of life – and even save lives. Knowing that only one of two in need of insulin has access to insulin today, InsuLife has the potential to contribute to fill a real medical need in developing countries and to simplify insulin treatment globally."

Learn more at

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved